



**HAL**  
open science

## Desperately seeking a home marrow niche for T-cell acute lymphoblastic leukaemia

Julien Calvo, Lucine Fahy, Benjamin Uzan, Françoise Pflumio

► **To cite this version:**

Julien Calvo, Lucine Fahy, Benjamin Uzan, Françoise Pflumio. Desperately seeking a home marrow niche for T-cell acute lymphoblastic leukaemia. *Advances in Biological Regulation*, 2019, 74, pp.100640 -. 10.1016/j.jbior.2019.100640 . hal-03489244

**HAL Id: hal-03489244**

**<https://hal.science/hal-03489244>**

Submitted on 21 Jul 2022

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

# 1 **Desperately seeking a home marrow niche for T-cell acute lymphoblastic** 2 **Leukaemia**

3 Julien Calvo<sup>1-4</sup>, Lucine Fahy<sup>1-4</sup>, Benjamin Uzan<sup>1-4</sup> and Françoise Pflumio<sup>1-4,\*</sup>

4

5 1. UMR Stabilité Génétique Cellules Souches et Radiations, Université de Paris, CEA, 18 route  
6 du Panorama, 92260 Fontenay-aux-Roses, France ;

7 2. UMR Stabilité Génétique Cellules Souches et Radiations, Université Paris-Saclay, CEA, 18  
8 route du Panorama, 92260 Fontenay-aux-Roses, France ;

9 3. Team Niche and Cancer in Hematopoiesis, U1274, Inserm, 18 route du Panorama, 92260  
10 Fontenay-aux-Roses, France ;

11

12 4. Laboratory of Hematopoietic stem cells and Leukemia/ Department of Stem Cells,  
13 Genomic Stability and Radiation/iRCM/JACOB/DRF, CEA, 18 route du Panorama, 92260  
14 Fontenay-aux-Roses, France. Laboratoire labellisé par l'Association pour la Recherche sur le  
15 Cancer

16

17 *\*Corresponding author: Dr. Françoise Pflumio, PhD.*

18 **Lead Contact** : Françoise Pflumio

## 19 **Address:**

20 Laboratoire des cellules souches hématopoïétiques et leucémiques – Team Niche et Cancer  
21 dans l'hématopoïèse, U1274 INSERM-IRCM, CEA, 18 route du Panorama, 92260, Fontenay-  
22 aux-Roses, France.

23 Phone : +33146548617

24 Fax : +33146549138

25 E-mail: francoise.pflumio@cea.fr

26

27 **Contributions:** F.P. and J.C. discussed and wrote the manuscript. L.F. and B.U. read the  
28 manuscript and gave important inputs.

29

## 30 **Abstract**

31 T-cell acute leukemia is a hematologic malignancy that results from the progressive  
32 acquisition of genomic abnormalities in T-cell progenitors/precursors. T-ALL is commonly  
33 thought to originate from the thymus albeit recent literature describes the possible  
34 acquisition of first oncogenic hits in hematopoietic progenitor cells of the bone marrow  
35 (BM). The journey of T-ALL from its arising to full blown expansion meets different  
36 microenvironments, including the BM in which leukemic cells settle down early after the  
37 disease spreading. We take advantage of recent literature to give an overview of important

38 cells and factors that participate in T-ALL, especially in the BM, arguing in favor of a home  
39 marrow niche for this rare leukemia.

40

#### 41 **Key words**

42 T-ALL, thymus, bone marrow, CXCL12, IL7, adipocytes.

43

#### 44 ***Introduction***

45 T-cell acute lymphoblastic leukaemia (T-ALL) constitutes a group of hematologic  
46 malignancies that result from the transformation of T cell progenitors. These pathologies  
47 concern children and adults. In the past twenty years, improvement in treatment protocols  
48 have contributed to a great amelioration of patient survival (Pui and Evans, 2013).  
49 Nevertheless, 15% of young patients and 45% of adults still relapse, which are of very bad  
50 prognosis (Litzow and Ferrando, 2015). Finding new ways to treat those patients is thus an  
51 important goal for ongoing research in the T-ALL field.

52 The knowledge accumulated from DNA sequencing and from functional T-ALL mouse models  
53 indicates that this blood disorder arises from the collaborative action of several oncogenic  
54 hits. Around 10-20 genomic abnormalities are the basis of this T-cell precursors'  
55 transformation (Girardi et al., 2017; Zhang et al., 2012). It is the accumulation of gain and  
56 loss of function of very diverse cell regulators that lead normal T cell precursors to lose their  
57 ability to fully differentiate into mature and functional T lymphocytes and to gain important  
58 survival and proliferative features, ultimately resulting in leukaemia (Belver and Ferrando,  
59 2016; Girardi et al., 2017) (Figure 1). It has long been admitted that T-ALL development  
60 occurs in the thymus where normal T cell differentiation takes place (Blom and Spits, 2006).  
61 Mouse models of early T-ALL development, using targeted oncogene expression in early T  
62 cells, such as in double negative (DN) CD4/CD8 thymocytes, have pointed these cells as  
63 putative cells of origin in certain T-ALL (McCormack et al., 2010; Tremblay et al., 2010).  
64 Experiments in which for instance LMO2 or LMO1 and TAL1 transcription factor expression  
65 was enforced in mouse DN3 T cell progenitors showed acquisition of self-renewal properties  
66 (Gerby et al., 2014; McCormack et al., 2010; Tremblay et al., 2010), and further  
67 transformation required additional genomic modifications, such as *Notch1*, *KRAS* or *NRAS*  
68 mutations, implicated in T cell engagement or in signal transduction pathways (García-  
69 Ramírez et al., 2018). In humans, the question relative to T-ALL pre-leukemic/cell of origin  
70 has been challenged using two main strategies. In one hand, enforced expression of

71 oncoproteins, such as NOTCH1/3, TLX3, TAL1/LMO2, in cord blood or bone marrow (BM)  
72 CD34<sup>+</sup> cells, forced to follow a T cell differentiation path using specific culture conditions or  
73 after transplantation in immune-deficient mice, was attempted as a way to dissect the early  
74 steps of T-ALL (De Smedt et al., 2002; García-Peydró et al., 2018; Pike-Overzet et al., 2007;  
75 Renou et al., 2017). Except for the work described in (García-Peydró et al., 2018), these  
76 attempts did not lead full blown leukaemia to develop, probably due to missing important  
77 secondary signals. However T cell progenitors accumulated as a result of a differentiation  
78 blockage and these progenitors were assimilated to pre-leukemic cells (De Smedt et al.,  
79 2002; Pike-Overzet et al., 2007; Renou et al., 2017). The second strategy, recently published,  
80 consisted in targeted sequencing of RNA from single hematopoietic CD34<sup>+</sup>CD38<sup>-</sup> progenitor  
81 cells sorted from the BM of T-ALL patients. The results indicated that in half T-ALL tested, a  
82 few multipotent cells held a hand of mutations found in leukemic cells, outlining the fact  
83 that these BM stem/progenitors may be cells of origin in human T-ALL (De Bie et al., 2018).  
84 As a matter of fact, as T-ALL progresses from the first genomic hit to the full spectrum of  
85 mutations and further expands to invade the body, the leukemic cells are in close contact  
86 with different microenvironments - thymus and blood infiltrated organs, including BM - that  
87 may impact their intrinsic behaviour as well as their chemo-sensitivity to treatments (Figure  
88 2).

89 Here we review the current knowledge of the relationships between the BM components  
90 and T-ALL. We especially focus our attention on late steps, when leukaemia has already  
91 spread in patient BM and blood. We question the current description of marrow niches of T-  
92 ALL.

93

#### 94 ***BM : a place to go for T-ALL?***

95 The diagnosis of leukaemia in patients copes with high infiltration rate of blood and BM  
96 (>20%), by immature looking blood cells. In the case of T-ALL, the blast cells originate from  
97 the thymus where progressive genetic abnormalities, such as translocation, gene fusion and  
98 mutations, have gradually accumulated in T cell precursors leading to uncontrolled cell  
99 growth, proliferation, survival and differentiation arrest to a point where undifferentiated  
100 highly proliferating cells start invading the whole organism (Girardi et al., 2017). How  
101 leukemic cells quit the thymus to disseminate to other body sites and whether there is a  
102 specific migration to the BM, is still unclear (Passaro et al., 2016; Vadillo et al., 2018). What

103 is much well known is how normal T cells transit within the thymus, from cortex to medulla,  
104 as they mature and how they eventually exit towards the blood when they reach their final  
105 differentiation stage (James et al., 2018). Upregulation of surface receptors such as CC-  
106 chemokine receptor 7 (CCR7) and expression of Semaphorin 3E receptor PlexinD1 are crucial  
107 to the T cell precursors from the thymic cortex to enter the medulla rich area following a  
108 gradient of CCR7-ligands CCL19 and CCL21 and thus further progress in the differentiation  
109 (Choi et al., 2008; Kwan and Killeen, 2004; Ueno et al., 2004). In later T cell differentiation  
110 stages, differential expression of CD69, CD62L and sphingosine-1-phosphate receptor 1  
111 (S1PR1) allows mature T cells to leave the thymus and reach the blood circulation. Finely  
112 tuned S1P levels, the ligand of S1PR1, are necessary to avoid intrathymic accumulation of  
113 newly produced mature T cells, that is orchestrated by different cells, such as thymic  
114 epithelial, stromal and endothelial cells, the latest being the gate keeper between the  
115 thymic microenvironment and the blood circulation (James et al., 2018). Because T-ALL cells  
116 are mostly restricted to pre-cortical or cortical precursors, i.e. that did not underwent  
117 sufficient differentiation to achieve the passage in the medulla, one can expect that  
118 mechanisms driving T-ALL emigration out of the thymus may involve molecules that are  
119 detected in the early steps of differentiation. CCR7 does not seem to be crucial in this  
120 phenomenon since deletion of CCR7 did not hamper Notch1-induced T-ALL migration,  
121 development and propagation. Only central nervous system invasion by T-ALL was modified  
122 in absence of CCR7 (Buonamici et al., 2009) albeit this result is debated (Jost et al., 2016).  
123 The chemokine receptor CXCR4 is widely expressed in newly diagnosed human T-ALL and in  
124 mouse models (Pitt et al., 2015) (*and our own results*) and its ligand CXCL12 is predominantly  
125 produced by the thymic cortex, and not by the medulla (Lucas et al., 2017). Albeit the role of  
126 CXCR4 in mature T cells exit from the thymus is debated (James et al., 2018), one may  
127 hypothesize that as leukaemia expands in the thymic cortex, a shortage in CXCL12 due to  
128 high consumption by pre-leukemic/leukemic cells may allow the “unfed” ones to start  
129 leaving the thymic environment and to find a lodgement in secondary CXCL12 producing  
130 niches, such as the BM. This “consumption” mechanism has been proposed to explain why  
131 the level of Interleukin 7 (IL7) is lower in the plasma of T-ALL patients compared to controls  
132 (Silva et al., 2011) as previous analyses showed IL7 circulating levels may be regulated by  
133 consumption (Park et al., 2004). Treatment of mice with the CXCR4 antagonist AMD3100  
134 redistributes leukocytes from primary immune organs, such as thymus and BM, to secondary

135 immune organs (Liu et al., 2015) indicating that preventing CXCR4 activation helps T cells to  
136 detach and recirculate. In the same idea, it is reported that T-ALL expansion perturbs the  
137 thymus architecture (García-Ramírez et al., 2018). In this context, cortical thymic epithelial  
138 cells (cTECs) may progressively be lost as a consequence of T-ALL intra-thymic development  
139 and because cTECs are CXCL12 producing cells (Lucas et al., 2017), their shortage during  
140 disease development may also lead to decreased levels of local consumable CXCL12 and help  
141 T-ALL cells to egress from the thymus.

142

### 143 ***BM: a place to be for T-ALL?***

144 BM is a major site in which T-ALL leukemic cells are detected during the leukaemia process  
145 and after their intra-venous transplantation in mouse recipients (De Keersmaecker et al.,  
146 2010; Hawkins et al., 2016; Passaro et al., 2015; Poglio et al., 2016). Getting into the BM  
147 microenvironment requires many steps such as adhesion on endothelial cells and  
148 extravasation from the blood circulation to enter the bone cavity. Albeit these mechanisms  
149 are well described for normal patrolling T cells that enter lymph nodes, precise information  
150 is missing for T-ALL when invading the BM (Vadillo et al., 2018). Once in the BM, leukemic  
151 cells need to find a proper niche among the very diverse BM microenvironment that would  
152 allow them to survive and proliferate (Morrison and Scadden, 2014). Recent studies have  
153 described the localization of T-ALL cells close to BM perivascular stromal and vascular cells  
154 shortly after leukemic cell injection (Pitt et al., 2015). Even though vascular endothelial cells  
155 (VEC) are not the main source of CXCL12 in the BM (Ding and Morrison, 2013; Greenbaum et  
156 al., 2013; Tikhonova et al., 2019), Pitt and colleagues demonstrated that CXCL12 specifically  
157 produced by VEC is necessary for the maintenance and progression of T-ALL *in vivo* (Pitt et  
158 al., 2015). These results remind the role of VEC-derived CXCL12 in maintaining  
159 hematopoietic stem cells (HSC) but were unexpected given that osteoblasts constitute a  
160 niche for lymphoid progenitors in BM (Ding and Morrison, 2013; Greenbaum et al., 2013).  
161 Conditional deletion of CXCL12 in VEC or treatment with a CXCR4 antagonist significantly  
162 decreased T-ALL propagation, indicating that VEC and production of CXCL12 are important  
163 for T-ALL development once BM is reached (Pitt et al., 2015). This observation fits with  
164 another study that showed an impact of CXCL12/CXCR4 in T-ALL migration, survival and  
165 expansion (Passaro et al., 2015). However, a more recent study that surveyed T-ALL  
166 localization close to osteoblasts, perivascular mesenchymal stem/progenitor cells and

167 vasculature using intra-vital microscopy, reported stochastic distribution of leukemic cells  
168 relative to these three cell BM components, rather than stable niche, and a high motility  
169 rarely restricted to the vicinity of any specific cell types or structures (Hawkins et al., 2016).  
170 These controversial results are not explained by the leukemic models studied, as similar  
171 oncogenic activation was used to induce T-ALL from mouse progenitors and human T-ALL  
172 were as well studied in both works. One main difference is the mouse BM location in which  
173 T-ALL initiation was explored, tibia vs calvaria (Hawkins et al., 2016; Pitt et al., 2015), which  
174 may imprint different behaviour to leukemic cells. A previous report showed substantial  
175 heterogeneity between calvaria and epiphyses and diaphysis of long bones in terms of bone  
176 remodelling activity, blood volume fraction and hypoxia (Lassailly et al., 2013). T-ALL are also  
177 very much dependent on a specific cytokine, that is IL7 (Barata et al., 2004, 2001). IL7 is  
178 crucial for normal T cell development and the expression of its receptor, IL7R $\alpha$ /CD127,  
179 varies in thymocytes according to the differentiation stages, being high in early T cells, lower  
180 in DP CD4<sup>+</sup>CD8<sup>+</sup> and re-induced in late SP mature T cells in accordance with the production  
181 of IL7 by cTECs (Akashi et al., 1998; James et al., 2018; Plum et al., 1996). So it is not  
182 surprising that about 70% of T-ALL, that are precursor T cells, express IL7R and respond to  
183 IL7 (Barata et al., 2004; Karawajew et al., 2000). *In vitro*, IL7 is a major cytokine to add in  
184 culture medium to grow T-ALL from patients (Armstrong et al., 2009; Scupoli et al., 2003;  
185 Yost et al., 2013) and recent development of a human anti- IL7R $\alpha$  antibody indicated  
186 efficient leukaemia cytotoxicity *in vitro* and delayed T-ALL development *in vivo* (Akkapeddi et  
187 al., 2019). Interestingly IL7/IL7R interaction does not similarly drive the activation of  
188 downstream STAT5, PI3K/Akt/mTOR and MEK/Erk pathways in normal and malignant states  
189 (Oliveira et al., 2019), indicating specific targeting of leukemic cells may be found. Notch  
190 activation, another important Receptor/ligand pathway in normal T cell differentiation  
191 (Radtke et al., 2010), is also implicated in T-ALL development, propagation and maintenance  
192 (Armstrong et al., 2009; Weng et al., 2004). It is expressed concomitantly to IL7/IL7R in the  
193 thymus compartments where they cooperate to induce proliferation of T cell progenitors  
194 while suppressing their non-T cell fates (García-Peydró et al., 2006), in relation with the fact  
195 that Notch1 signalling drives IL7R $\alpha$  expression in early T cells and leukaemia (González-  
196 García et al., 2009). Importantly, both *Notch1* and *IL7R $\alpha$*  genes are targeted by gain of  
197 function mutations in T-ALL patients (Weng et al., 2004; Zenatti et al., 2011) further outlining  
198 the importance of both signalling pathways in supporting leukemia survival/expansion. Of

199 note, *Notch1* mutations appear late during the oncogenic process, indicating only  
200 cooperative effect with other premium genomic abnormalities (De Bie et al., 2018). Notch  
201 ligands Delta-like 1 and Delta-like 4 (DLL1, DLL4) that are the major ligands of Notch1  
202 implicated in thymic T cell development, and IL7 are produced by different cells of the BM  
203 microenvironment. Indeed, single cell RNA sequencing analyses identified VE-cadherin  
204 positive endothelial cells as the exclusive DLL1/DLL4 expressing BM non-hematopoietic cells  
205 whereas IL7 is detected in Leptin receptor positive (LepR<sup>+</sup>) mesenchymal stromal/stem cells  
206 (MSC) (Baryawno et al., 2019; Tikhonova et al., 2019). DLL4 that has also been detected in  
207 osteoblastic cells (Yu et al., 2015) induces T-ALL expansion *in vitro* and *in vivo* (Minuzzo et al.,  
208 2015). Interestingly, CXCL12 is much more broadly expressed than the Notch ligands  
209 DLL4/DLL1 and IL7, but its highest expression is detected in LepR<sup>+</sup> cells that also produce IL7  
210 (Tikhonova et al., 2019). This observation is supported by a recent paper describing the  
211 coincident production of IL7 and CXCL12 by unique peri-sinusoidal stromal cells, that  
212 aggregate pro-B cells and HSC at very close spots, representing another potential cellular  
213 niche for T-ALL (Balzano et al., 2019). Other growth factors/cytokines have been shown to  
214 help T-ALL to propagate. Insulin-growth factor 1 (IGF1) is one of them and its receptor is  
215 broadly expressed in T-ALL as a result of Notch1 activation (Medyouf et al., 2011) whereas  
216 transcripts of IGF1 are detected almost exclusively in osteoblastic cells (Tikhonova et al.,  
217 2019). Blocking or deleting IGF1 receptor in mouse T-ALL has major effects in the  
218 progression of leukemia *in vivo* with low leukemia-initiating activity being observed in such  
219 conditions (Medyouf et al., 2011). Interestingly, T-ALL can also contribute to its own growth  
220 through education of dendritic cells to secrete high IGF1 levels (Triplett et al., 2016).  
221 Speaking about cross-talks between the BM and T-ALL, an interesting finding concerns the  
222 implication of the pro-inflammatory cytokine, IL18, in T-ALL propagation. Indeed, a recent  
223 study described the presence of enhanced IL18 levels in the circulation of T-ALL patients  
224 (Uzan et al., 2014). IL18 receptor is expressed in T-ALL cells and interfering with its  
225 expression using a shRNA approach as well as blocking IL18 with a neutralizing antibody or  
226 using knock-out mice, greatly limits leukemia expansion in mouse and human T-ALL models  
227 (Uzan et al., 2014). IL18 is not produced by leukemic cells but rather by endogenous BM  
228 cells, including stromal cells (Uzan et al., 2014). Single cell RNA seq identified few IL18  
229 expressing cells among LepR<sup>+</sup> stromal cells, indicating potential overlap with IL7 and CXCL12  
230 producing cells (<http://aifantislabs.com/niche> from (Tikhonova et al., 2019). As a sum up, T-ALL



231 cells that home to BM can count on many different local interactions to help their growth  
232 and propagation, providing mechanistic clues on why the BM is a “warm nest” for this  
233 leukaemia (Figure 3).

234

### 235 ***BM, BM... which BM are you talking about?***

236 BM niches are numerous and very diverse in the human body, partly due to the architecture  
237 of the different bones. With aging, the BM composition changes and marrow niches become  
238 more and more infiltrated with adipose tissue; in the neonate, the BM is entirely  
239 hematopoietic and during the first year of life the conversion from hematopoietic, or red, to  
240 fatty, or yellow, marrow begins (Vogler and Murphy, 1988). The completion time of  
241 hematopoietic to adipocytic conversion is different if one considers the appendicular and  
242 the axial skeleton, the latest proceeds throughout life whereas the first one is over by the  
243 time of skeletal maturity (Laor and Jaramillo, 2009). Moreover the red to yellow marrow  
244 conversion follows a very specific pattern starting distally at the phalanges and moving  
245 centrally towards the axial skeleton. In bones such as humerus, sternum and clavicle, fatty  
246 transformation starts in the epiphysis, proceeds through the diaphysis and ends in the  
247 metaphysis (Zawin and Jaramillo, 1993). Thus looking at BM niches in a given (long) bone, at  
248 young adult time, in mouse, may only provide a limited, even though very informative,  
249 portray of the BM microenvironment at steady state or upon stressful conditions, such as  
250 after chemical myeloablation or after leukaemia development (Baryawno et al., 2019;  
251 Tikhonova et al., 2019; Zhou et al., 2017), and not taking into account the evident man to  
252 mouse bone architecture differences. With this caveats in mind, one may question whether  
253 the leukemic cells behave similarly in different bones, where for instance the BM red to  
254 yellow conversion state is not at the same levels. This question is important because BM  
255 adipocytes are known as modulators of BM cell components, such as osteoblastic and  
256 hematopoietic cells (Ambrosi et al., 2017). Interestingly a recent study investigated the  
257 metabolic and cell cycle state of T-ALL recovered from two different fat-containing mouse  
258 BM sites, i.e. thoracic and tail vertebrae, in mouse and xenograft models. Compared to  
259 thoracic/red BM, T-ALL cells from tail vertebrae/yellow BM were in a lower metabolic and  
260 quiescent state that correlated with higher T-ALL intrinsic chemoresistance to cell cycle-  
261 targeting drugs (Cahu et al., 2017). This state was reversible upon cultures in permissive  
262 conditions and after secondary transplants, as leukemic cells reached long bones/red BM

263 areas (Cahu et al., 2017). Albeit the exact mechanisms depicting the effect of the adipocyte-  
264 rich BM on T-ALL are currently unknown, these results are in line with recent analyses  
265 showing that BM adipocytes are negative regulators of the hematopoietic  
266 microenvironment (Naveiras et al., 2009). However, more recent studies showed that  
267 hematopoietic recovery after myeloablation is supported by BM adipocytes from long bones  
268 but not from caudal vertebrae that seem to influence not only hematopoiesis but also BM  
269 vascularization (Zhou et al., 2017). These last results indicate an even higher degree of  
270 variability between the BM cell content, even for well-known adipocyte lineage, of different  
271 bones, outlining the difficulties of understanding the exact relationship between leukaemia  
272 and its microenvironment in bones. The study of leukaemia development in tail and thorax  
273 vertebrae also pinpoints the fact that when leukaemia treatment efficiency is assessed by  
274 BM aspiration in a defined bone spot, one may not forget that other infiltrated bones may  
275 provide another reality.

276

### 277 ***BM and T-ALL marriage: not yet concluded?***

278 Considering the signals available in the BM, it is thus expected that T-ALL are to go and stay  
279 in the medullary niches, some of them supporting chemoresistance during treatments. *Ex-*  
280 *vivo* experiments have shown that T-ALL in contact with MSC have low reactive oxygen  
281 species (ROS), in relation with enhanced mitochondrial fragmentation. Low ROS levels  
282 participate in MSC-mediated T-ALL resistance to aracytin and methotrexate (Cai et al., 2016).  
283 It has also been observed that leukemic cells may transfer mitochondria to MSC in presence  
284 of these drugs through intercellular nanotube formation, and this phenomenon decreases  
285 ROS levels in leukemic cells, similarly contributing to chemo resistance (Wang et al., 2018).  
286 Nevertheless, as mentioned earlier in the text, T-ALL cells, like grasshoppers in a fertile field,  
287 can devastate and reduce cell diversity. Studies have shown that in T-ALL invaded BM,  
288 osteoblasts disappear as a consequence of aberrant activation of Notch1 in osteoblastic  
289 progenitors, and this coincides with HSC/progenitor functional loss (Hawkins et al., 2016;  
290 Wang et al., 2016). Moreover, MSC isolated from the BM of T-ALL patients become  
291 senescent and are unable to differentiate into adipocytes, osteocytes and chondrocytes (Lim  
292 et al., 2016), a state that may be linked to massive mitochondrial transfer from leukemic  
293 cells to MSC (Wang et al., 2018). Interestingly, a similar mechanism was described to explain

294 HSC protection from senescence in the BM niche, e.g. a direct transfer of ROS mediated by  
295 Connexin-43 from HSC to BM stromal cells (Taniguchi Ishikawa et al., 2012).  
296 The remaining burning question is whether the “grasshopper effect” of T-ALL, that may not  
297 be restricted to this leukemia type, is totally reversible. Indeed, elimination of leukemic cells  
298 from the BM by chemotherapeutic agents may not fully restore the normal BM  
299 microenvironment supporting properties, leading to dysfunctional long term production of  
300 hematopoietic cells.

301

### 302 ***That’s all folks!***

303 Much efforts have been produced to understand the reciprocal relations between BM  
304 microenvironment and T-ALL in the recent years. The current results provide a still  
305 preliminary picture of the cell/factors exchanges that may be refined with the recent  
306 development of single cell analyses and of very precise intra-vital microscopy. Questions  
307 relative to the chemoprotection of leukemic cells by the diverse BM microenvironments are  
308 still pending but will undoubtedly be resolved in a near future. This may open to  
309 complementary strategies to target resistant cells in their home marrow nest.

310

311 The authors have no competing interests to declare.

312

### 313 ***Acknowledgements***

314 We wish to thank the LSHL lab members for the dynamic discussion generated around the  
315 writing process. We apologize to the colleagues whose work we did not cite, as a matter of  
316 space limitation. LF is a PhD fellow from Ligue Nationale Contre le Cancer. The team is  
317 funded by Institut National pour la Santé et la Recherche Médicale (INSERM), Commissariat  
318 à l’Energie atomique et aux Energies Alternatives (CEA), Université de Paris and Université  
319 Paris/Saclay, Institut du Cancer (INCA), and Association pour la Recherche contre le Cancer  
320 (Equipe labellisée ARC).

321

322

323

324

325 **References**

- 326 Akkapeddi, P., Fragoso, R., Hixon, J.A., Ramalho, A.S., Oliveira, M.L., Carvalho, T., Gloger,  
327 A., Matasci, M., Corzana, F., Durum, S.K., Neri, D., Bernardes, G.J.L., Barata, J.T., 2019. A  
328 fully human anti-IL-7R $\alpha$  antibody promotes antitumor activity against T-cell acute  
329 lymphoblastic leukemia. *Leukemia*. <https://doi.org/10.1038/s41375-019-0434-8>  
330
- 331 Ambrosi, T.H., Scialdone, A., Graja, A., Gohlke, S., Jank, A.-M., Bocian, C., Woelk, L., Fan,  
332 H., Logan, D.W., Schürmann, A., Saraiva, L.R., Schulz, T.J., 2017. Adipocyte Accumulation  
333 in the Bone Marrow during Obesity and Aging Impairs Stem Cell-Based Hematopoietic and  
334 Bone Regeneration. *Cell Stem Cell* 20, 771-784.e6.  
335 <https://doi.org/10.1016/j.stem.2017.02.009>  
336
- 337 Armstrong, F., Brunet de la Grange, P., Gerby, B., Rouyez, M.-C., Calvo, J., Fontenay, M.,  
338 Boissel, N., Dombret, H., Baruchel, A., Landman-Parker, J., Roméo, P.-H., Ballerini, P.,  
339 Pflumio, F., 2009. NOTCH is a key regulator of human T-cell acute leukemia initiating cell  
340 activity. *Blood* 113, 1730–1740. <https://doi.org/10.1182/blood-2008-02-138172>  
341
- 342 Balzano, M., De Grandis, M., Vu Manh, T.-P., Chasson, L., Bardin, F., Farina, A., Sergé, A.,  
343 Bidaut, G., Charbord, P., Héroult, L., Bailly, A.-L., Cartier-Michaud, A., Boned, A., Dalod,  
344 M., Duprez, E., Genever, P., Coles, M., Bajenoff, M., Xerri, L., Aurrand-Lions, M., Schiff,  
345 C., Mancini, S.J.C., 2019. Nidogen-1 Contributes to the Interaction Network Involved in Pro-  
346 B Cell Retention in the Peri-sinusoidal Hematopoietic Stem Cell Niche. *Cell Rep* 26, 3257-  
347 3271.e8. <https://doi.org/10.1016/j.celrep.2019.02.065>  
348
- 349 Barata, J.T., Cardoso, A.A., Nadler, L.M., Boussiotis, V.A., 2001. Interleukin-7 promotes  
350 survival and cell cycle progression of T-cell acute lymphoblastic leukemia cells by down-  
351 regulating the cyclin-dependent kinase inhibitor p27(kip1). *Blood* 98, 1524–1531.  
352 <https://doi.org/10.1182/blood.v98.5.1524>  
353
- 354 Barata, J.T., Keenan, T.D., Silva, A., Nadler, L.M., Boussiotis, V.A., Cardoso, A.A., 2004.  
355 Common gamma chain-signaling cytokines promote proliferation of T-cell acute  
356 lymphoblastic leukemia. *Haematologica* 89, 1459–1467.  
357
- 358 Baryawno, N., Przybylski, D., Kowalczyk, M.S., Kfoury, Y., Severe, N., Gustafsson, K.,  
359 Kokkaliaris, K.D., Mercier, F., Tabaka, M., Hofree, M., Dionne, D., Papazian, A., Lee, D.,  
360 Ashenberg, O., Subramanian, A., Vaishnav, E.D., Rozenblatt-Rosen, O., Regev, A., Scadden,  
361 D.T., 2019. A Cellular Taxonomy of the Bone Marrow Stroma in Homeostasis and Leukemia.  
362 *Cell* 177, 1915-1932.e16. <https://doi.org/10.1016/j.cell.2019.04.040>  
363
- 364 Belver, L., Ferrando, A., 2016. The genetics and mechanisms of T cell acute lymphoblastic  
365 leukaemia. *Nat. Rev. Cancer* 16, 494–507. <https://doi.org/10.1038/nrc.2016.63>  
366
- 367 Blom, B., Spits, H., 2006. Development of human lymphoid cells. *Annu. Rev. Immunol.* 24,  
368 287–320. <https://doi.org/10.1146/annurev.immunol.24.021605.090612>  
369
- 370 Buonamici, S., Trimarchi, T., Ruocco, M.G., Reavie, L., Cathelin, S., Mar, B.G., Klinakis, A.,  
371 Lukyanov, Y., Tseng, J.-C., Sen, F., Gehrie, E., Li, M., Newcomb, E., Zavadil, J., Meruelo,  
372 D., Lipp, M., Ibrahim, S., Efstratiadis, A., Zagzag, D., Bromberg, J.S., Dustin, M.L., Aifantis,

373 I., 2009. CCR7 signalling as an essential regulator of CNS infiltration in T-cell leukaemia.  
374 Nature 459, 1000–1004. <https://doi.org/10.1038/nature08020>  
375

376 Cahu, X., Calvo, J., Poglio, S., Prade, N., Colsch, B., Arcangeli, M.-L., Leblanc, T., Petit, A.,  
377 Baleyrier, F., Baruchel, A., Landman-Parker, J., Junot, C., Larghero, J., Ballerini, P.,  
378 Delabesse, E., Uzan, B., Pflumio, F., 2017. Bone marrow sites differently imprint dormancy  
379 and chemoresistance to T-cell acute lymphoblastic leukemia. *Blood Adv* 1, 1760–1772.  
380 <https://doi.org/10.1182/bloodadvances.2017004960>  
381

382 Cai, J., Wang, J., Huang, Y., Wu, H., Xia, T., Xiao, J., Chen, X., Li, H., Qiu, Y., Wang, Y.,  
383 Wang, T., Xia, H., Zhang, Q., Xiang, A.P., 2016. ERK/Drp1-dependent mitochondrial fission  
384 is involved in the MSC-induced drug resistance of T-cell acute lymphoblastic leukemia cells.  
385 *Cell Death Dis* 7, e2459. <https://doi.org/10.1038/cddis.2016.370>  
386

387 Choi, Y.I., Duke-Cohan, J.S., Ahmed, W.B., Handley, M.A., Mann, F., Epstein, J.A.,  
388 Clayton, L.K., Reinherz, E.L., 2008. PlexinD1 glycoprotein controls migration of positively  
389 selected thymocytes into the medulla. *Immunity* 29, 888–898.  
390 <https://doi.org/10.1016/j.immuni.2008.10.008>  
391

392 De Bie, J., Demeyer, S., Alberti-Servera, L., Geerdens, E., Segers, H., Broux, M., De  
393 Keersmaecker, K., Michaux, L., Vandenberghe, P., Voet, T., Boeckx, N., Uyttebroeck, A.,  
394 Cools, J., 2018. Single-cell sequencing reveals the origin and the order of mutation  
395 acquisition in T-cell acute lymphoblastic leukemia. *Leukemia* 32, 1358–1369.  
396 <https://doi.org/10.1038/s41375-018-0127-8>  
397

398 De Keersmaecker, K., Real, P.J., Gatta, G.D., Palomero, T., Sulis, M.L., Tosello, V., Van  
399 Vlierberghe, P., Barnes, K., Castillo, M., Sole, X., Hadler, M., Lenz, J., Aplan, P.D., Kelliher,  
400 M., Kee, B.L., Pandolfi, P.P., Kappes, D., Gounari, F., Petrie, H., Van der Meulen, J.,  
401 Speleman, F., Paietta, E., Racevskis, J., Wiernik, P.H., Rowe, J.M., Soulier, J., Avran, D.,  
402 Cavé, H., Dastugue, N., Raimondi, S., Meijerink, J.P.P., Cordon-Cardo, C., Califano, A.,  
403 Ferrando, A.A., 2010. The TLX1 oncogene drives aneuploidy in T cell transformation. *Nat.*  
404 *Med.* 16, 1321–1327. <https://doi.org/10.1038/nm.2246>  
405

406 De Smedt, M., Reynvoet, K., Kerre, T., Taghon, T., Verhasselt, B., Vandekerckhove, B.,  
407 Leclercq, G., Plum, J., 2002. Active form of Notch imposes T cell fate in human progenitor  
408 cells. *J. Immunol.* 169, 3021–3029. <https://doi.org/10.4049/jimmunol.169.6.3021>  
409

410 Ding, L., Morrison, S.J., 2013. Haematopoietic stem cells and early lymphoid progenitors  
411 occupy distinct bone marrow niches. *Nature* 495, 231–235.  
412 <https://doi.org/10.1038/nature11885>  
413

414 García-Peydró, M., de Yébenes, V.G., Toribio, M.L., 2006. Notch1 and IL-7 receptor  
415 interplay maintains proliferation of human thymic progenitors while suppressing non-T cell  
416 fates. *J. Immunol.* 177, 3711–3720. <https://doi.org/10.4049/jimmunol.177.6.3711>  
417

418 García-Peydró, M., Fuentes, P., Mosquera, M., García-León, M.J., Alcain, J., Rodríguez, A.,  
419 García de Miguel, P., Menéndez, P., Weijer, K., Spits, H., Scadden, D.T., Cuesta-Mateos, C.,  
420 Muñoz-Calleja, C., Sánchez-Madrid, F., Toribio, M.L., 2018. The NOTCH1/CD44 axis  
421 drives pathogenesis in a T cell acute lymphoblastic leukemia model. *J. Clin. Invest.* 128,  
422 2802–2818. <https://doi.org/10.1172/JCI92981>

423  
424 García-Ramírez, I., Bhatia, S., Rodríguez-Hernández, G., González-Herrero, I., Walter, C.,  
425 González de Tena-Dávila, S., Parvin, S., Haas, O., Woessmann, W., Stanulla, M., Schrappe,  
426 M., Dugas, M., Natkunam, Y., Orfao, A., Domínguez, V., Pintado, B., Blanco, O., Alonso-  
427 López, D., De Las Rivas, J., Martín-Lorenzo, A., Jiménez, R., García Criado, F.J., García  
428 Cenador, M.B., Lossos, I.S., Vicente-Dueñas, C., Borkhardt, A., Hauer, J., Sánchez-García, I.,  
429 2018. Lmo2 expression defines tumor cell identity during T-cell leukemogenesis. *EMBO J.*  
430 37. <https://doi.org/10.15252/embj.201798783>  
431  
432 Gerby, B., Tremblay, C.S., Tremblay, M., Rojas-Sutterlin, S., Herblot, S., Hébert, J.,  
433 Sauvageau, G., Lemieux, S., Lécuyer, E., Veiga, D.F.T., Hoang, T., 2014b. SCL, LMO1 and  
434 Notch1 reprogram thymocytes into self-renewing cells. *PLoS Genet.* 10, e1004768.  
435 <https://doi.org/10.1371/journal.pgen.1004768>  
436  
437 Girardi, T., Vicente, C., Cools, J., De Keersmaecker, K., 2017. The genetics and molecular  
438 biology of T-ALL. *Blood* 129, 1113–1123. <https://doi.org/10.1182/blood-2016-10-706465>  
439  
440 González-García, S., García-Peydró, M., Martín-Gayo, E., Ballestar, E., Esteller, M.,  
441 Bornstein, R., de la Pompa, J.L., Ferrando, A.A., Toribio, M.L., 2009. CSL-MAML-  
442 dependent Notch1 signaling controls T lineage-specific IL-7R $\alpha$  gene expression in  
443 early human thymopoiesis and leukemia. *J. Exp. Med.* 206, 779–791.  
444 <https://doi.org/10.1084/jem.20081922>  
445  
446 Greenbaum, A., Hsu, Y.-M.S., Day, R.B., Schuettpelz, L.G., Christopher, M.J., Borgerding,  
447 J.N., Nagasawa, T., Link, D.C., 2013. CXCL12 in early mesenchymal progenitors is required  
448 for haematopoietic stem-cell maintenance. *Nature* 495, 227–230.  
449 <https://doi.org/10.1038/nature11926>  
450  
451 Hawkins, E.D., Duarte, D., Akinduro, O., Khorshed, R.A., Passaro, D., Nowicka, M.,  
452 Straszowski, L., Scott, M.K., Rothery, S., Ruivo, N., Foster, K., Waibel, M., Johnstone,  
453 R.W., Harrison, S.J., Westerman, D.A., Quach, H., Gribben, J., Robinson, M.D., Purton, L.E.,  
454 Bonnet, D., Lo Celso, C., 2016. T-cell acute leukaemia exhibits dynamic interactions with  
455 bone marrow microenvironments. *Nature* 538, 518–522. <https://doi.org/10.1038/nature19801>  
456  
457 James, K.D., Jenkinson, W.E., Anderson, G., 2018. T-cell egress from the thymus: Should I  
458 stay or should I go? *J. Leukoc. Biol.* 104, 275–284. <https://doi.org/10.1002/JLB.1MR1217-496R>  
459  
460  
461 Jost, T.R., Borga, C., Radaelli, E., Romagnani, A., Perruzza, L., Omodho, L., Cazzaniga, G.,  
462 Biondi, A., Indraccolo, S., Thelen, M., Te Kronnie, G., Grassi, F., 2016. Role of CXCR4-  
463 mediated bone marrow colonization in CNS infiltration by T cell acute lymphoblastic  
464 leukemia. *J. Leukoc. Biol.* 99, 1077–1087. <https://doi.org/10.1189/jlb.5MA0915-394R>  
465  
466 Karawajew, L., Ruppert, V., Wuchter, C., Kösser, A., Schrappe, M., Dörken, B., Ludwig, W.-  
467 D., 2000. Inhibition of in vitro spontaneous apoptosis by IL-7 correlates with Bcl-2 up-  
468 regulation, cortical/mature immunophenotype, and better early cytoreduction of childhood T-  
469 cell acute lymphoblastic leukemia. *Blood* 96, 297–306.  
470

471 Kwan, J., Killeen, N., 2004. CCR7 Directs the Migration of Thymocytes into the Thymic  
472 Medulla. *The Journal of Immunology* 172, 3999–4007.  
473 <https://doi.org/10.4049/jimmunol.172.7.3999>  
474

475 Laor, T., Jaramillo, D., 2009. MR imaging insights into skeletal maturation: what is normal?  
476 *Radiology* 250, 28–38. <https://doi.org/10.1148/radiol.2501071322>  
477

478 Lassailly, F., Foster, K., Lopez-Onieva, L., Currie, E., Bonnet, D., 2013. Multimodal imaging  
479 reveals structural and functional heterogeneity in different bone marrow compartments:  
480 functional implications on hematopoietic stem cells. *Blood* 122, 1730–1740.  
481 <https://doi.org/10.1182/blood-2012-11-467498>  
482

483 Lim, M., Pang, Y., Ma, S., Hao, S., Shi, H., Zheng, Y., Hua, C., Gu, X., Yang, F., Yuan, W.,  
484 Cheng, T., 2016. Altered mesenchymal niche cells impede generation of normal  
485 hematopoietic progenitor cells in leukemic bone marrow. *Leukemia* 30, 154–162.  
486 <https://doi.org/10.1038/leu.2015.210>  
487

488 Litzow, M.R., Ferrando, A.A., 2015. How I treat T-cell acute lymphoblastic leukemia in  
489 adults. *Blood* 126, 833–841. <https://doi.org/10.1182/blood-2014-10-551895>  
490

491 Liu, Q., Li, Z., Gao, J.-L., Wan, W., Ganesan, S., McDermott, D.H., Murphy, P.M., 2015.  
492 CXCR4 antagonist AMD3100 redistributes leukocytes from primary immune organs to  
493 secondary immune organs, lung, and blood in mice. *Eur. J. Immunol.* 45, 1855–1867.  
494 <https://doi.org/10.1002/eji.201445245>  
495

496 Lucas, B., White, A.J., Parnell, S.M., Henley, P.M., Jenkinson, W.E., Anderson, G., 2017.  
497 Progressive Changes in CXCR4 Expression That Define Thymocyte Positive Selection Are  
498 Dispensable For Both Innate and Conventional  $\alpha\beta$ T-cell Development. *Scientific Reports* 7,  
499 5068. <https://doi.org/10.1038/s41598-017-05182-7>  
500

501 McCormack, M.P., Young, L.F., Vasudevan, S., de Graaf, C.A., Codrington, R., Rabbitts,  
502 T.H., Jane, S.M., Curtis, D.J., 2010. The Lmo2 oncogene initiates leukemia in mice by  
503 inducing thymocyte self-renewal. *Science* 327, 879–883.  
504 <https://doi.org/10.1126/science.1182378>  
505

506 Medyouf, H., Gusscott, S., Wang, H., Tseng, J.-C., Wai, C., Nemirovsky, O., Trumpp, A.,  
507 Pflumio, F., Carboni, J., Gottardis, M., Pollak, M., Kung, A.L., Aster, J.C., Holzenberger, M.,  
508 Weng, A.P., 2011. High-level IGF1R expression is required for leukemia-initiating cell  
509 activity in T-ALL and is supported by Notch signaling. *J. Exp. Med.* 208, 1809–1822.  
510 <https://doi.org/10.1084/jem.20110121>  
511

512 Minuzzo, S., Agnusdei, V., Pusceddu, I., Pinazza, M., Moserle, L., Masiero, M., Rossi, E.,  
513 Crescenzi, M., Hoey, T., Ponzoni, M., Amadori, A., Indraccolo, S., 2015. DLL4 regulates  
514 NOTCH signaling and growth of T acute lymphoblastic leukemia cells in NOD/SCID mice.  
515 *Carcinogenesis* 36, 115–121. <https://doi.org/10.1093/carcin/bgu223>  
516

517 Morrison, S.J., Scadden, D.T., 2014. The bone marrow niche for haematopoietic stem cells.  
518 *Nature* 505, 327–334. <https://doi.org/10.1038/nature12984>  
519

520 Naveiras, O., Nardi, V., Wenzel, P.L., Hauschka, P.V., Fahey, F., Daley, G.Q., 2009. Bone-  
521 marrow adipocytes as negative regulators of the haematopoietic microenvironment. *Nature*  
522 460, 259–263. <https://doi.org/10.1038/nature08099>  
523

524 Oliveira, M.L., Akkapeddi, P., Ribeiro, D., Melão, A., Barata, J.T., 2019. IL-7R-mediated  
525 signaling in T-cell acute lymphoblastic leukemia: An update. *Adv Biol Regul* 71, 88–96.  
526 <https://doi.org/10.1016/j.jbior.2018.09.012>  
527

528 Park, J.-H., Yu, Q., Erman, B., Appelbaum, J.S., Montoya-Durango, D., Grimes, H.L., Singer,  
529 A., 2004. Suppression of IL7Ralpha transcription by IL-7 and other prosurvival cytokines: a  
530 novel mechanism for maximizing IL-7-dependent T cell survival. *Immunity* 21, 289–302.  
531 <https://doi.org/10.1016/j.immuni.2004.07.016>  
532

533 Passaro, D., Irigoyen, M., Catherinet, C., Gachet, S., Da Costa De Jesus, C., Lasgi, C., Tran  
534 Quang, C., Ghysdael, J., 2015. CXCR4 Is Required for Leukemia-Initiating Cell Activity in T  
535 Cell Acute Lymphoblastic Leukemia. *Cancer Cell* 27, 769–779.  
536 <https://doi.org/10.1016/j.ccell.2015.05.003>  
537

538 Passaro, D., Quang, C.T., Ghysdael, J., 2016. Microenvironmental cues for T-cell acute  
539 lymphoblastic leukemia development. *Immunol. Rev.* 271, 156–172.  
540 <https://doi.org/10.1111/imr.12402>  
541

542 Pike-Overzet, K., de Ridder, D., Weerkamp, F., Baert, M.R.M., Verstegen, M.M.A.,  
543 Brugman, M.H., Howe, S.J., Reinders, M.J.T., Thrasher, A.J., Wagemaker, G., van Dongen,  
544 J.J.M., Staal, F.J.T., 2007. Ectopic retroviral expression of LMO2, but not IL2Rgamma,  
545 blocks human T-cell development from CD34+ cells: implications for leukemogenesis in  
546 gene therapy. *Leukemia* 21, 754–763. <https://doi.org/10.1038/sj.leu.2404563>  
547

548 Pitt, Lauren A., Tikhonova, A.N., Hu, H., Trimarchi, T., King, B., Gong, Y., Sanchez-Martin,  
549 M., Tsirigos, A., Littman, D.R., Ferrando, A.A., Morrison, S.J., Fooksman, D.R., Aifantis, I.,  
550 Schwab, S.R., 2015. CXCL12-Producing Vascular Endothelial Niches Control Acute T Cell  
551 Leukemia Maintenance. *Cancer Cell* 27, 755–768. <https://doi.org/10.1016/j.ccell.2015.05.002>  
552

553 Poglio, S., Lewandowski, D., Calvo, J., Caye, A., Gros, A., Laharanne, E., Leblanc, T.,  
554 Landman-Parker, J., Baruchel, A., Soulier, J., Ballerini, P., Clappier, E., Pflumio, F., 2016.  
555 Speed of leukemia development and genetic diversity in xenograft models of T cell acute  
556 lymphoblastic leukemia. *Oncotarget* 7, 41599–41611.  
557 <https://doi.org/10.18632/oncotarget.9313>  
558

559 Pui, C.-H., Evans, W.E., 2013. A 50-year journey to cure childhood acute lymphoblastic  
560 leukemia. *Semin. Hematol.* 50, 185–196. <https://doi.org/10.1053/j.seminhematol.2013.06.007>  
561 Radtke, F., Fasnacht, N., Macdonald, H.R., 2010. Notch signaling in the immune system.  
562 *Immunity* 32, 14–27. <https://doi.org/10.1016/j.immuni.2010.01.004>  
563

564 Renou, L., Boelle, P.-Y., Deswarte, C., Spicuglia, S., Benyoucef, A., Calvo, J., Uzan, B.,  
565 Belhocine, M., Cieslak, A., Landman-Parker, J., Baruchel, A., Asnafi, V., Pflumio, F.,  
566 Ballerini, P., Naguibneva, I., 2017b. Homeobox protein TLX3 activates miR-125b expression  
567 to promote T-cell acute lymphoblastic leukemia. *Blood Advances* 1, 733–747.  
568 <https://doi.org/10.1182/bloodadvances.2017005538>  
569



570 Scupoli, M.T., Vinante, F., Krampera, M., Vincenzi, C., Nadali, G., Zampieri, F., Ritter,  
571 M.A., Eren, E., Santini, F., Pizzolo, G., 2003. Thymic epithelial cells promote survival of  
572 human T-cell acute lymphoblastic leukemia blasts: the role of interleukin-7. *Haematologica*  
573 88, 1229–1237.

574  
575 Silva, A., Laranjeira, A.B.A., Martins, L.R., Cardoso, B.A., Demengeot, J., Yunes, J.A.,  
576 Seddon, B., Barata, J.T., 2011. IL-7 contributes to the progression of human T-cell acute  
577 lymphoblastic leukemias. *Cancer Res.* 71, 4780–4789. [https://doi.org/10.1158/0008-](https://doi.org/10.1158/0008-5472.CAN-10-3606)  
578 [5472.CAN-10-3606](https://doi.org/10.1158/0008-5472.CAN-10-3606)

579  
580 Taniguchi Ishikawa, E., Gonzalez-Nieto, D., Ghiaur, G., Dunn, S.K., Ficker, A.M., Murali,  
581 B., Madhu, M., Gutstein, D.E., Fishman, G.I., Barrio, L.C., Cancelas, J.A., 2012. Connexin-  
582 43 prevents hematopoietic stem cell senescence through transfer of reactive oxygen species to  
583 bone marrow stromal cells. *Proc. Natl. Acad. Sci. U.S.A.* 109, 9071–9076.  
584 <https://doi.org/10.1073/pnas.1120358109>

585  
586 Tikhonova, A.N., Dolgalev, I., Hu, H., Sivaraj, K.K., Hoxha, E., Cuesta-Domínguez, Á.,  
587 Pinho, S., Akhmetzyanova, I., Gao, J., Witkowski, M., Guillaumot, M., Gutkin, M.C., Zhang,  
588 Y., Marier, C., Diefenbach, C., Kousteni, S., Heguy, A., Zhong, H., Fooksman, D.R., Butler,  
589 J.M., Economides, A., Frenette, P.S., Adams, R.H., Satija, R., Tsirigos, A., Aifantis, I., 2019.  
590 The bone marrow microenvironment at single-cell resolution. *Nature* 569, 222–228.  
591 <https://doi.org/10.1038/s41586-019-1104-8>

592  
593 Tremblay, M., Tremblay, C.S., Herblot, S., Aplan, P.D., Hébert, J., Perreault, C., Hoang, T.,  
594 2010. Modeling T-cell acute lymphoblastic leukemia induced by the SCL and LMO1  
595 oncogenes. *Genes Dev.* 24, 1093–1105. <https://doi.org/10.1101/gad.1897910>

596  
597 Triplett, T.A., Cardenas, K.T., Lancaster, J.N., Hu, Z., Selden, H.J., Jasso, G.J.,  
598 Balasubramanyam, S., Chan, K., Li, L., Chen, X., Marcogliese, A.N., Davé, U.P., Love, P.E.,  
599 Ehrlich, L.I.R., 2016. Endogenous dendritic cells from the tumor microenvironment support  
600 T-ALL growth via IGF1R activation. *Proc. Natl. Acad. Sci. U.S.A.* 113, E1016-1025.  
601 <https://doi.org/10.1073/pnas.1520245113>

602  
603 Ueno, T., Saito, F., Gray, D.H.D., Kuse, S., Hieshima, K., Nakano, H., Kakiuchi, T., Lipp,  
604 M., Boyd, R.L., Takahama, Y., 2004. CCR7 Signals Are Essential for Cortex–Medulla  
605 Migration of Developing Thymocytes. *Journal of Experimental Medicine* 200, 493–505.  
606 <https://doi.org/10.1084/jem.20040643>

607  
608 Uzan, B., Poglio, S., Gerby, B., Wu, C.-L., Gross, J., Armstrong, F., Calvo, J., Cahu, X.,  
609 Deswarte, C., Dumont, F., Passaro, D., Besnard-Guérin, C., Leblanc, T., Baruchel, A.,  
610 Landman-Parker, J., Ballerini, P., Baud, V., Ghysdael, J., Baleyrier, F., Porteu, F., Pflumio,  
611 F., 2014. Interleukin-18 produced by bone marrow-derived stromal cells supports T-cell acute  
612 leukaemia progression. *EMBO Mol Med* 6, 821–834.  
613 <https://doi.org/10.1002/emmm.201303286>

614  
615 Vadillo, E., Dorantes-Acosta, E., Pelayo, R., Schnoor, M., 2018. T cell acute lymphoblastic  
616 leukemia (T-ALL): New insights into the cellular origins and infiltration mechanisms  
617 common and unique among hematologic malignancies. *Blood Rev.* 32, 36–51.  
618 <https://doi.org/10.1016/j.blre.2017.08.006>

619

620 Vogler, J.B., Murphy, W.A., 1988. Bone marrow imaging. *Radiology* 168, 679–693.  
621 <https://doi.org/10.1148/radiology.168.3.3043546>  
622

623 Wang, J., Liu, X., Qiu, Y., Shi, Y., Cai, J., Wang, B., Wei, X., Ke, Q., Sui, X., Wang, Y.,  
624 Huang, Y., Li, H., Wang, T., Lin, R., Liu, Q., Xiang, A.P., 2018. Cell adhesion-mediated  
625 mitochondria transfer contributes to mesenchymal stem cell-induced chemoresistance on T  
626 cell acute lymphoblastic leukemia cells. *J Hematol Oncol* 11, 11.  
627 <https://doi.org/10.1186/s13045-018-0554-z>  
628

629 Wang, W., Zimmerman, G., Huang, X., Yu, S., Myers, J., Wang, Y., Moreton, S., Nthale, J.,  
630 Awadallah, A., Beck, R., Xin, W., Wald, D., Huang, A.Y., Zhou, L., 2016. Aberrant Notch  
631 Signaling in the Bone Marrow Microenvironment of Acute Lymphoid Leukemia Suppresses  
632 Osteoblast-Mediated Support of Hematopoietic Niche Function. *Cancer Res.* 76, 1641–1652.  
633 <https://doi.org/10.1158/0008-5472.CAN-15-2092>  
634

635 Weng, A.P., Ferrando, A.A., Lee, W., Morris, J.P., Silverman, L.B., Sanchez-Irizarry, C.,  
636 Blacklow, S.C., Look, A.T., Aster, J.C., 2004. Activating mutations of NOTCH1 in human T  
637 cell acute lymphoblastic leukemia. *Science* 306, 269–271.  
638 <https://doi.org/10.1126/science.1102160>  
639

640 Yost, A.J., Shevchuk, O.O., Gooch, R., Gusscott, S., You, M.J., Ince, T.A., Aster, J.C., Weng,  
641 A.P., 2013. Defined, serum-free conditions for in vitro culture of primary human T-ALL  
642 blasts. *Leukemia* 27, 1437–1440. <https://doi.org/10.1038/leu.2012.337>  
643


644 Yu, V.W.C., Saez, B., Cook, C., Lotinun, S., Pardo-Saganta, A., Wang, Y.-H., Lymperi, S.,  
645 Ferraro, F., Raaijmakers, M.H.G.P., Wu, J.Y., Zhou, L., Rajagopal, J., Kronenberg, H.M.,  
646 Baron, R., Scadden, D.T., 2015. Specific bone cells produce DLL4 to generate thymus-  
647 seeding progenitors from bone marrow. *J. Exp. Med.* 212, 759–774.  
648 <https://doi.org/10.1084/jem.20141843>  
649

650 Zawin, J.K., Jaramillo, D., 1993. Conversion of bone marrow in the humerus, sternum, and  
651 clavicle: changes with age on MR images. *Radiology* 188, 159–164.  
652 <https://doi.org/10.1148/radiology.188.1.8511291>  
653


654 Zenatti, P.P., Ribeiro, D., Li, W., Zuurbier, L., Silva, M.C., Paganin, M., Tritapoe, J., Hixon,  
655 J.A., Silveira, A.B., Cardoso, B.A., Sarmiento, L.M., Correia, N., Toribio, M.L., Kobarg, J.,  
656 Horstmann, M., Pieters, R., Brandalise, S.R., Ferrando, A.A., Meijerink, J.P., Durum, S.K.,  
657 Yunes, J.A., Barata, J.T., 2011. Oncogenic IL7R gain-of-function mutations in childhood T-  
658 cell acute lymphoblastic leukemia. *Nat. Genet.* 43, 932–939. <https://doi.org/10.1038/ng.924>  
659

660 Zhang, J., Ding, L., Holmfeldt, L., Wu, G., Heatley, S.L., Payne-Turner, D., Easton, J., Chen,  
661 X., Wang, J., Rusch, M., Lu, C., Chen, S.-C., Wei, L., Collins-Underwood, J.R., Ma, J.,  
662 Roberts, K.G., Pounds, S.B., Ulyanov, A., Becksfort, J., Gupta, P., Huether, R., Kriwacki,  
663 R.W., Parker, M., McGoldrick, D.J., Zhao, D., Alford, D., Espy, S., Bobba, K.C., Song, G.,  
664 Pei, D., Cheng, C., Roberts, S., Barbato, M.I., Campana, D., Coustan-Smith, E., Shurtleff,  
665 S.A., Raimondi, S.C., Kleppe, M., Cools, J., Shimano, K.A., Hermiston, M.L., Doulatov, S.,  
666 Eppert, K., Laurenti, E., Notta, F., Dick, J.E., Basso, G., Hunger, S.P., Loh, M.L., Devidas,  
667 M., Wood, B., Winter, S., Dunsmore, K.P., Fulton, R.S., Fulton, L.L., Hong, X., Harris, C.C.,  
668 Dooling, D.J., Ochoa, K., Johnson, K.J., Obenauer, J.C., Evans, W.E., Pui, C.-H., Naeve,  
669 C.W., Ley, T.J., Mardis, E.R., Wilson, R.K., Downing, J.R., Mullighan, C.G., 2012. The

670 genetic basis of early T-cell precursor acute lymphoblastic leukaemia. *Nature* 481, 157–163.  
671 <https://doi.org/10.1038/nature10725>  
672  
673 Zhou, B.O., Yu, H., Yue, R., Zhao, Z., Rios, J.J., Naveiras, O., Morrison, S.J., 2017. Bone  
674 marrow adipocytes promote the regeneration of stem cells and haematopoiesis by secreting  
675 SCF. *Nat. Cell Biol.* 19, 891–903. <https://doi.org/10.1038/ncb3570>



**Figure 1: Classification and frequencies of the main molecular targets of oncogenic abnormalities in T-ALL. Shown are the different factors distributed in categories being more or less frequently affected in leukemic cells**



**Figure 2:** Simplified model of T-ALL development starting in the BM, proceeding in the thymus and further invading BM again (adapted from [Garcia Ramirez I. et al, Embo J., 2018](#)).

Mesenchymal stem/stromal cells  
(vascular perisinusoidal)




Figure 3: Overview of extrinsic factors and non-hematopoietic BM cells known to regulate T-ALL (from Pitt *et al.*, 2015, Passaro *et al.*, 2015; Armstrong *et al.*, 2009; Tikhonova *et al.*, 2019; Cahu *et al.*, 2017; Balzano *et al.*, 2019; Medyouf *et al.*, 2011; Passaro *et al.*, 2015; Silva *et al.*, 2011; Uzan *et al.*, 2014; Baryoawno *et al.*, 2019)